Gait and attentional performance in freezers under methylphenidate

Area of Science:

• Neurology
• Movement Disorders
• Cognitive Neuroscience

Background:

• Freezing of gait (FoG) in Parkinson's disease (PD) is linked to attentional resource allocation.
• Previous research suggested methylphenidate may reduce FoG and gait hypokinesia in PD patients off dopaminergic drugs.
• Methylphenidate is known to enhance attention.

Purpose of the Study:

• To investigate if methylphenidate reduces the cognitive-motor interference in PD patients experiencing FoG.
• To compare attentional performance between patients treated with methylphenidate and those on placebo.

Main Methods:

• A randomized, double-blind, placebo-controlled study involving 24 PD patients with FoG.
• Patients received methylphenidate (1mg/kg/day) or placebo for three months, assessed after an L-dopa challenge.
• Primary outcome: stride length ratio during dual-task versus free gait; secondary outcomes: reaction times on attention tasks and FoG severity.

Main Results:

• No significant difference was found in the dual-task gait interference between the methylphenidate and placebo groups.
• Attentional performance did not differ significantly between the methylphenidate and placebo groups.
• Exclusion of trials with FoG episodes from analysis.

Conclusions:

• Methylphenidate did not alleviate gait hypokinesia in PD patients undergoing dopaminergic treatment.
• The observed reduction in FoG episodes with methylphenidate in prior studies may not be linked to improved attention or reduced dual-task interference.
• Further research is needed to understand methylphenidate's effects on FoG in PD patients on dopaminergic therapy.